After Breakout Year, Moderna on Track to Generate $15B+ in 2022 Thanks to More Demand, Higher Prices: Analysts


All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version). 

Visit and follow us on Instagram at @crg_globalresearch.


The Covid vaccine business is a multibillion dollar endeavour. The mRNA vaccine is unapproved and experimental.

It has been authorized for so-called emergency use on behalf of Big Pharma. “Emergency Use” is not justified.

This article documents the process of unregulated enrichment of Big Pharma,  focussing on Moderna Inc’s mRNA Covid vaccine.


Moderna is hard at work ramping up production of its mRNA COVID-19 vaccine, which is projected to reap over $19 billion for the company by year’s end. But given that the pandemic is easing in parts of the world, what’s less certain is how 2022 will play out.

After a breakout year, Moderna sees strong reason to believe 2021 won’t be a one-off boom year. That’s thanks to the predicted need for booster shots and additional supply deals coupled with stronger pricing power, Jefferies analysts wrote to clients Thursday following a conversation with CEO Stéphane Bancel.

The Jefferies team thinks Moderna could drive $15 billion in 2022 revenues, with an upper limit of $30 billion. Where the company lands will depend on how the pandemic progresses, fear of infection and whether the company can produce future products, like a combo shot against COVID and the flu.

Plus, it’s possible that Moderna could start charging more per dose given its high efficacy, reliable manufacturing and absence of serious side effects that have plagued other vaccine developers, the analysts said.

Moderna has said it can churn out between 800 million to 1 billion doses this year, and about 3 billion by 2022. The company has been ramping up supply lines with CDMO heavyweights and is planning a massive expansion at its own U.S.-based facilities to meet its lofty supply expectations.

With more doses coming down the line, Moderna is already engaging with countries who weren’t able to secure supply this year, as well as with those that previously ordered adenovirus shots, Jefferies analysts wrote.

And discussions are ongoing with nations that already have supply deals, given that many have yet to begin inoculating children. The company’s shot has been used in people ages 18 and older, although the company is working to expand its use to those as young as 12, including in the U.S.

The Cambridge, Massachusetts-based biotech is also developing three potential booster shots to target troublesome virus variants, including a lower dose of its original vaccine, one developed to target the variant first found in South Africa, and a combination of the two.

It’s thought that some countries will “want to ensure there are adequate orders” for booster shots as early as six months to a year after the first vaccines were administered, the Jefferies team said.

Pandemic shots aren’t the only sales prospects Moderna has in its back pocket, Jefferies said. The mRNA developer is also working on a shot for seasonal influenza, with initial results anticipated by the end of the year.


Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Children’s Health Defense

Articles by: Noah Higgins-Dunn

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected] contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]